Podcast Episodes
Back to Search
Episode 375: Renal Cancer 2024 Highlights
David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC
1 year, 10 months ago
Episode 374: Mechanisms of HIF Resistance
Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.
1 year, 10 months ago
Episode 373: KEYNOTE-564 Asian OSとANNARの解説
JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです
1 year, 10 months ago
Episode 372: FDA Accelerated Approval Process
Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.
1 year, 10 months ago
Episode 371: TROPICS-04 Results from ESMO Asia
Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.
1 year, 10 months ago
Episode 370: Artificial Intelligence in Medical Oncology
Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology
1 year, 10 months ago
Episode 369: Paper of the Month with Bishoy Faltas
Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication
1 year, 11 months ago
Episode 368: Radiomics in RCC: Live from IKCS
Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism
1 year, 11 months ago
Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer
Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.
1 year, 11 months ago
Episode 366: ARPIs in Prostate Cancer - Are They Different?
Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.
1 year, 11 months ago